Sunesis Pharmaceuticals Inc.

NASDAQ: SNSSHealthcare / Biotechnology / USA
0.8500+0.0200+2.41%Vol 216 9891Y Perf -55.90%
Aug 21st, 2019 16:00
BID0.8500 ASK0.8700
Open0.8300 Previous Close0.8300
Pre-Market- After-Trading0.85
 - -%  - -%
Target Price
5.17 
Analyst Rating
Moderate Buy 2.00
Potencial %
508.24 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)95 
Earnings Rating
Strong Buy
Price Range Ratio 52wk %
31.55 
Earnings Date
7th Aug 2019

Today's Price Range

0.80000.8600

52wk Range

0.20002.26

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
8.97%
1 Month
7.59%
3 Months
-20.56%
6 Months
57.41%
1 Year
-55.90%
3 Years
-82.29%
5 Years
-97.95%
10 Years
-94.51%

Name / TickerPriceChg.Chg.%
SNSS0.85000.02002.41
AAPL212.642.28001.08
GOOG1 191.258.56000.72
MSFT138.791.53001.11
XOM69.720.69001.00
WFC45.000.32000.72
JNJ131.530.93000.71
FB183.55-0.2600-0.14
GE8.16-0.2200-2.63
JPM107.610.30000.28
Earnings HistoryEstimateReportedSurprise %
Q02 2019-0.10-0.0910.00
Q01 2019-0.18-0.1044.44
Q04 2018-0.22-0.1627.27
Q03 2018-0.24-0.1825.00
Q02 2018-0.26-0.2023.08
Q01 2018-0.29-0.2127.59
Q04 2017-0.25-0.2116.00
Q03 2017-0.37-0.43-16.22
Earnings Per EndEstimateRevision %Trend
9/2019 QR-0.0918.18Positive
12/2019 QR-0.1214.29Positive
12/2019 FY-0.409.09Positive
12/2020 FY-0.2513.79Positive
Next Report Date-
Estimated EPS Next Report-0.10
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume216 989
Shares Outstanding (in ths.)111 320
Trades Count1 119
Dollar Volume866 930
Avg. Volume916 196
Avg. Weekly Volume246 006
Avg. Monthly Volume395 737
Avg. Quarterly Volume1 026 654
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (50.00 %)
2 (50.00 %)
2 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (50.00 %)
2 (50.00 %)
2 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.00

Sunesis Pharmaceuticals Inc.

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

CEO: Dayton Misfeldt

Teplephone: +1 650 266-3500

Address: 395 Oyster Point Boulevard, South San Francisco 94080, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

44%56%

Bearish Bullish

59%41%

Bearish Bullish

51%49%

News